513 Effects of entecavir and lamivudine on advanced liver fibrosis after 48 weeks of treatment in patients with CHB infection: Results of three pivotal trials

Şimşek, Halis; Schiffe, E.; Goodman, Z.; Brett‐Smith, Helena; Klesczewski, K.; Kreter, Bruce

doi:10.1016/s0168-8278(06)80513-1

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Ishak fibrosis score improved in 38% 38 . In patients with severe fibrosis at baseline, the Ishak fibrosis score improved (≥1 point) in 53%, remained unchanged in 18% and worsened in 5% 39 . Continuation of treatment did not result in significantly improved treatment outcomes as the percentage of PCR‐negative subjects increased from 72% to 77% and ALT normalization increased from 71% to 84% after 96 weeks of treatment 38 .…”

Section: Lamivudinementioning

confidence: 94%

Review article: success and failure of nucleoside and nucleotide analogues in chronic hepatitis B

Leemans

Borg

Man

2007

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARY BackgroundStrong suppression of viral replication and normalization of alanine aminotransferase is feasible with nucleos(t)ide analogues. It is estimated viral replication and liver inflammation can be controlled in 90\% of patients with chronic hepatitis B with the current available treatments. AimTo review the studies currently available on the management of chronic hepatitis B with nucleos(t)ide analogues. ResultsAlthough very potent, nucleos(t)ide analogues are not effective in every patient. Some factors are known to influence treatment outcome, but many host and viral factors are still unknown. Stopping rules have to be defined to assess treatment efficacy in an early stage and change the regimen. Discontinuation of nucleos(t)ide analogues is often followed by reactivation of HBV. Data on the risk factors for relapse are necessary in order to decide if treatment can be safely discontinued. Another major drawback of nucleos(t)ide analogues is the emergence of resistance. The efficacy of compounds for the treatment of mutant virus and the impact of cross-resistance is largely unknown. The use of combination therapy to prevent resistance looks promising, but has to be proven. ConclusionsHBV has become a treatable disease, however much research is needed to optimize treatment for individual patients and treatment failures.

show abstract

Section: Lamivudinementioning

confidence: 94%

Review article: success and failure of nucleoside and nucleotide analogues in chronic hepatitis B

Leemans

Borg

Man

2007

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Entecavir

Calleja

Peñas

2008

Enfermedades Infecciosas y Microbiología Clínica

View full text Add to dashboard Cite

Chronic hepatitis B continues to be a serious problem worldwide. Because a high viral load is associated with greater progression to cirrhosis and hepatocarcinoma in these patients, new drugs that achieve rapid, potent and lasting suppression of viral replication must be sought. Entecavir is a new, highly potent antiviral agent; phase II and III studies have demonstrated this drug to be superior to placebo and lamivudine in patients with chronic hepatitis B virus in terms of histological improvement, efficacy in achieving suppression of viral replication and normalizing transaminase counts. The drug is well tolerated, since its adverse effects are usually mild or moderate and their incidence is similar to that found with placebo or lamivudine. Moreover, in treatment-naïve patients, no resistance has been observed after 3 years of therapy. However, in patients with prior resistance to lamivudine, the incidence of resistance is approximately 15% at 3 years. Further studies are required that compare this drug with other currently available therapeutic options, as well as longer term trials to evaluate its safety. It seems that entecavir will occupy a major place in the treatment of patients with chronic hepatitis B virus infection.

show abstract

Entecavir: nueva esperanza para el tratamiento de la hepatitis B crónica

Calleja

Peñas

2007

Gastroenterología y Hepatología

View full text Add to dashboard Cite

513 Effects of entecavir and lamivudine on advanced liver fibrosis after 48 weeks of treatment in patients with CHB infection: Results of three pivotal trials

Cited by 3 publications

References 0 publications

Review article: success and failure of nucleoside and nucleotide analogues in chronic hepatitis B

Review article: success and failure of nucleoside and nucleotide analogues in chronic hepatitis B

Entecavir

Entecavir: nueva esperanza para el tratamiento de la hepatitis B crónica

Contact Info

Product

Resources

About